Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA(R) Pediatrics

Sepracor's STEDESA(TM) (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA

Sepracor Reports Strong First Quarter 2009 Operating Results and Reiterates Financial Guidance for 2009

Sepracor Reports Preliminary Phase III Study Results for OMNARIS(R) HFA Nasal Aerosol in Seasonal Allergic Rhinitis

Sepracor Inc. Sets Conference Call and Webcast for First Quarter 2009 Operating Results

Sepracor Announces Patent Interference Proceedings (and Schedule) Against Wyeth for Claims Related to O-desmethylvenlafaxine Succinate (Marketed as PRISTIQ(R))

Sepracor Announces Submission of STEDESA((TM)) New Drug Application to FDA for Adjunctive Treatment of Epilepsy

Sepracor Files Patent Infringement Lawsuit Against Eszopiclone ANDA Filers

Sepracor Completes Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024

Sepracor Announces Final Settlement of XOPENEX(R) Inhalation Solution Patent Infringement Litigation with Barr Laboratories, Inc. and Grant of Non-Exclusive License to Barr and Teva Pharmaceuticals USA, Inc.

Sepracor Reports Preliminary Phase II Study Results for SEP-225441 for the Treatment of Generalized Anxiety Disorder

Sepracor Announces Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024

Sepracor Reports Fourth Quarter and Full-Year 2008 Operating Results

Sepracor Announces Strategic Corporate Restructuring and Workforce Reduction Plan in Addition to 2009 Financial Guidance

Sepracor Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2008 Operating Results

Results of Studies of Eslicarbazepine Acetate for the Treatment of Epilepsy to Be Presented at American Epilepsy Society Annual Meeting

Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting

Sepracor Inc. Reports 9.6% Increase in Revenue for Third Quarter and Tightens Range for Full-Year 2008 Financial Guidance

European Medicines Agency (EMEA) Issues Positive Opinion For LUNIVIA(R) (Eszopiclone) Marketing Authorization Application (MAA) In Europe

Sepracor Inc. Sets Conference Call and Webcast for Third Quarter Operating Results

New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy

ALVESCO(R) (Ciclesonide) Inhalation Aerosol Now Available in U.S. for Treatment of Asthma

LUNESTA(R) Next-Day Function and Discontinuation Data from a Long-Term 12-Week Study in Elderly Patients Presented at ECNP

Sepracor Announces Senior Management Appointments

Sepracor Inc. Reports Second Quarter 2008 Results

Sepracor Inc. Sets Conference Call and Webcast for Second Quarter Operating Results

Sepracor Announces Full Support of PhRMA's Revised Code on Interactions with Healthcare Professionals

Sepracor Inc. Presented Leadership Award for Contributions to Growth of Community

Sepracor Announces Phase III Data for Eslicarbazepine Acetate Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs

Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada

Sepracor Names Robert F. Scumaci as Chief Financial Officer

David P. Southwell to Resign as Chief Financial Officer of Sepracor

LUNESTA(R) Study of Patients with Insomnia and Co-Morbid Generalized Anxiety Disorder (GAD) Published in Archives of General Psychiatry

Sepracor Inc. Reports First Quarter 2008 Results, Certain Strategic Initiatives and Settlement of XOPENEX(R) Patent Litigation with Breath Limited

Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial Operations into Canada

Sepracor and Arrow Sign Global License and Development Agreement Covering Technology to Enhance Ciclesonide and BROVANA(R) Franchises

Sepracor Announces Final Settlement of XOPENEX(R) Inhalation Solution Patent Infringement Litigation with Breath Limited

Sepracor and Arrow Sign Global License and Development Agreement for XOPENEX(R)/Ipratropium Inhalation Solution Combination

Sepracor Inc. Sets Conference Call and Webcast for First Quarter Operating Results

Sepracor Launches ''My Allergies in America'' Web Site, a New Online Resource for Physicians and Nasal Allergy Sufferers

OMNARIS(TM) Nasal Spray Now Available by Prescription for Patients with Seasonal and Perennial Allergies

Sepracor Presents OMNARIS(TM) HFA Nasal Aerosol Large-Scale Phase II Study Data at American Academy of Allergy Asthma and Immunology (AAAAI)

Sepracor Presents Safety Data on OMNARIS(TM)AQ and OMNARIS(TM) HFA Nasal Sprays at American Academy of Allergy Asthma and Immunology (AAAAI)

Sepracor Announces Passing of Board Member James G. Andress

Sepracor Inc. Reports 2007 Fourth Quarter and Full-Year Results, Forecasts Stronger Revenue Growth for 2008

Sepracor Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2007 Operating Results

Sepracor Announces Internal Review of Government Price Reporting Matters

Sepracor Acquires Exclusive U.S. Rights to Nycomed's ALVESCO(R) HFA and OMNARIS(TM) AQ Products as Well as Ciclesonide Pipeline

Timothy J. Barberich to Resign as Executive Chairman of Sepracor and Will Continue to Serve as Chairman of the Board

Sepracor Inc. and Bial Announce Exclusive Licensing Agreement for Development and Commercialization of Anti-Epileptic Compound in United States and Canada

Sepracor Inc. Announces Completion of SEC Investigation

Sepracor Inc. Announces Appointment of Lisa Ricciardi as Board Member

Sepracor Inc. Announces the Establishment of a Unique Product-Specific Billing Code (or J-Code) for BROVANA(R)

Sepracor Inc. Announces Third Quarter 2007 Results and Planned Reduction in Operating Expenses for 2008

BROVANA(R) Inhalation Solution Study Data Presented at American College of Chest Physicians Annual Conference

Sepracor Inc. Sets Conference Call and Webcast for Third Quarter 2007 Operating Results

Sepracor Announces Senior Management Appointments as Part of Commercial Re-Organization

Sepracor Inc. and GlaxoSmithKline Announce International Alliance for Commercialization of LUNIVIA(R) (LUNESTA(R) in U.S.)

Sepracor Inc. Announces Second Quarter 2007 Results and Significant Milestone Events

Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe

Sepracor Inc. and Eisai Co. Ltd. Announce Partnership for Development and Commercialization of LUNESTA(R) in Japan

Sepracor Inc. Sets Conference Call and Webcast for Second Quarter 2007 Operating Results

Sepracor Issues Statement Regarding CMS Medicare Part B Reimbursement Change for XOPENEX(R) Inhalation Solution

Sepracor Announces Management Transition

Sepracor Announces First Quarter 2007 Results

BROVANA(R) Inhalation Solution Now Available by Prescription for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Sepracor Inc. Sets Conference Call and Webcast for First Quarter 2007 Operating Results

Sepracor Announces Publication of Additional Data from Lunesta(R) Insomnia-Depression Study in the Journal of Clinical Sleep Medicine

Sepracor Announces Fourth Quarter and Full Year 2006 Results

Sepracor Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2006 Operating Results

Results of Sepracor's LUNESTA(R) Next-Day Driving Study in Patients with Primary Insomnia Presented at American College of Neuropsychopharmacology Meeting

Data Show Sepracor's Lunesta(R) Improved Insomnia in Patients with Co-Existing Generalized Anxiety Disorder

LUNESTA(R) Perimenopause-Menopause Study Published in Journal of Obstetrics and Gynecology

XOPENEX HFA(R) Data Presented at American College of Allergy, Asthma and Immunology Annual Meeting

XOPENEX HFA(R) Data to Be Presented at American College of Allergy, Asthma and Immunology Annual Meeting

Sepracor Announces Third Quarter 2006 Operating Results

Data for XOPENEX(R) Brand of Levalbuterol Presented at American College of Chest Physicians Annual Conference

Data for XOPENEX(R) Brand of Levalbuterol Presented at American College of Chest Physicians Annual Conference

BROVANA(R) (Arformoterol Tartrate) Inhalation Solution Study Data Presented at American College of Chest Physicians Annual Conference

XOPENEX(R) Brand of Levalbuterol Data to Be Presented at American College of Chest Physicians Annual Meeting

BROVANA(R) (Arformoterol Tartrate) Inhalation Solution Data to Be Presented at American College of Chest Physicians Annual Meeting

Newly Published Data Show Efficacy and Safety of LUNESTA(R) in Elderly Patients with Insomnia

FDA Approves Sepracor's BROVANA(R) (Arformoterol Tartrate) Inhalation Solution for Chronic Obstructive Pulmonary Disease

Arformoterol Study Data Presented at European Respiratory Society Annual Congresss

Sepracor Announces Presentation of Arformoterol Data at the European Respiratory Society Annual Congress

Sepracor Delays Filing of Quarterly Report on Form 10-Q

Sepracor Announces Second Quarter 2006 Operating Results

Sepracor Announces Second Quarter 2006 Operating Results

Sepracor Inc. Sets Conference Call and Webcast for Second Quarter 2006 Operating Results

Sepracor Announces Presentation of LUNESTA(TM) Data at Associated Professional Sleep Societies 20th Anniversary Meeting

Sepracor Announces Presentation of LUNESTA(TM) Posters at Associated Professional Sleep Societies Annual Meeting

Sepracor Announces Presentation of LUNESTA(TM) Data at Associated Professional Sleep Societies Annual Meeting